Efficacy of Phosphodiesterase Type 5 Inhibitor Treatment in Men with Erectile Dysfunction and Dyslipidemia: A Post Hoc Analysis of the Vardenafil Statin Study

被引:12
作者
Miner, Martin M. [1 ]
Barnes, Allison [2 ]
Janning, Stephen [2 ]
机构
[1] Brown Univ, Sch Med, Providence, RI 02912 USA
[2] GlaxoSmithKline, Res Triangle Pk, NC USA
关键词
Male Erectile Dysfunction; Dyslipidemia; Metabolic Syndrome; Vardenafil Treatment in Dyslipidemia; METABOLIC SYNDROME; ENDOTHELIAL DYSFUNCTION; SEXUAL DYSFUNCTION; CARDIAC RISK; HEALTH; PREVALENCE; CONSENSUS; DISEASE;
D O I
10.1111/j.1743-6109.2010.01766.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction. Dyslipidemia occurs often in subjects with erectile dysfunction (ED), but there is little information about how this condition affects ED treatment responses. Aim. To determine whether low-density lipoprotein cholesterol (LDL-C) levels, total cholesterol (TC)/high-density lipoprotein cholesterol (HDL-C) ratio; or the presence of metabolic syndrome influenced efficacy of vardenafil in men with ED and dyslipidemia. Methods. Post hoc subgroup analysis of a 12-week study of the influence of lipid levels and presence of metabolic syndrome on the efficacy of vardenafil as measured by International Index of Erectile Function-Erectile Function (IIEF-EF) domain score, responses to Sexual Encounter Profile (SEP) SEP2 and SEP3 questions, duration of erection leading to successful intercourse, and erection duration regardless of the answer to SEP3. Lipid values were obtained at study start, after patients had received at least 3 months of therapy with a statin. Main Outcome Measures. Outcomes in subjects with LDL-C < 100, >= 100 to < 130, or >= 130 mg/dL [< 2.59, >= 2.59 to < 3.36, or >= 3.36 mmol/L]; TC/HDL-C ratio < 3.5 vs. >= 3.5, and presence or absence of metabolic syndrome. Results. Vardenafil improved all endpoints evaluated compared with placebo in all subgroups, however, nominally significant treatment by subgroup interaction terms did not follow a distinct pattern. Increasing LDL-C (P = 0.033), but not TC/HDL-C ratio or metabolic syndrome, was associated with an increase in treatment response measured by the IIEF-EF domain score. Responses to SEP3 were nominally influenced by LDL-C levels (P = 0.019), but were not significantly influenced by TC/HDL-C ratio, or the metabolic syndrome. Only higher TC/HDL-C ratios (>= 3.5) were associated with larger treatment differences in duration of erection leading to successful intercourse (P = 0.028). Conclusions. Vardenafil was effective in men with dyslipidemia regardless of LDL-C levels, TC/HDL-C ratio, and/or presence of metabolic syndrome. Despite the known presence of ED and dyslipidemia, other cardiovascular risk factors were apparently not aggressively managed. Miner MM, Barnes A, and Janning S. Efficacy of phosphodiesterase type 5 inhibitor treatment in men with erectile dysfunction and dyslipidemia: A post hoc analysis of the vardenafil statin study. J Sex Med 2010;7:1937-1947.
引用
收藏
页码:1937 / 1947
页数:11
相关论文
共 50 条
[41]   A placebo-controlled exploratory study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder [J].
Giuliano, Francois A. ;
Lamb, Janice ;
Crossland, Anna ;
Haughie, Scott ;
Ellis, Peter ;
Tamimi, Nihad A. M. .
BJU INTERNATIONAL, 2010, 106 (05) :666-673
[42]   Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis [J].
Athyros, Vasilios G. ;
Tziomalos, Konstantinos ;
Gossios, Thomas D. ;
Griva, Theodora ;
Anagnostis, Panagiotis ;
Kargiotis, Konstantinos ;
Pagourelias, Efstathios D. ;
Theocharidou, Eleni ;
Karagiannis, Asterios ;
Mikhailidis, Dimitri P. .
LANCET, 2010, 376 (9756) :1916-1922
[43]   Safety and efficacy of empagliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post hoc analysis of data from the SACRA study [J].
Okada, Kenta ;
Hoshide, Satoshi ;
Kato, Mitsutoshi ;
Kanegae, Hiroshi ;
Ishibashi, Shun ;
Kario, Kazuomi .
JOURNAL OF CLINICAL HYPERTENSION, 2021, 23 (04) :860-869
[44]   Liver function effects of SGLT2 inhibitor and GLP-1 receptor agonist combination treatment in patients with type 2 diabetes (post hoc analysis of RECAP study) [J].
Tsuriya, Daisuke ;
Kobayashi, Kazuo ;
Takeshita, Kei ;
Hashimoto, Takuya ;
Kimura, Moritsugu ;
Muta, Yoshimi ;
Yokomizo, Hisashi ;
Takashi, Yuichi ;
Tsukamoto, Shunichiro ;
Tamura, Kouichi ;
Kanasaki, Keizo ;
Kawanami, Daiji ;
Toyoda, Masao .
JOURNAL OF DIABETES INVESTIGATION, 2025, 16 (07) :1243-1253
[45]   Efficacy and safety of phosphodiesterase type 5 inhibitors on primary premature ejaculation in men receiving selective serotonin reuptake inhibitors therapy: a systematic review and meta-analysis [J].
Men, C. ;
Yu, L. ;
Yuan, H. ;
Cui, Y. .
ANDROLOGIA, 2016, 48 (09) :978-985
[46]   Informal caregiver's socio demographic profile for community-dwelling women and men with mild to moderate Alzheimer's disease, compliance, and satisfaction to treatment: A post-hoc analysis of the AXEPT study [J].
Colombo, Delia ;
Zagni, Emanuela ;
Rossini, Paolo Maria ;
Di Cioccio, Luigi ;
Gragnaniello, Daniela ;
Di Cortemiglia, Emilio Luda ;
Attar, Mahmood ;
Simoni, Lucia ;
Haggiag, Shalom ;
Bernabei, Roberto .
HEALTH CARE FOR WOMEN INTERNATIONAL, 2023, 44 (12) :1622-1637
[47]   Desirable Low-Density Lipoprotein Cholesterol Levels for Preventing Stroke Recurrence A Post Hoc Analysis of the J-STARS Study (Japan Statin Treatment Against Recurrent Stroke) [J].
Hosomi, Naohisa ;
Kitagawa, Kazuo ;
Nagai, Yoji ;
Nakagawa, Yoko ;
Aoki, Shiro ;
Nezu, Tomohisa ;
Kagimura, Tatsuo ;
Maruyama, Hirofumi ;
Origasa, Hideki ;
Minematsu, Kazuo ;
Uchiyama, Shinichiro ;
Matsumoto, Masayasu .
STROKE, 2018, 49 (04) :865-+
[48]   Changes in serum levels of liver-related parameters, uric acid, and hemoglobin in patients with type 2 diabetes mellitus under treatment with tofogliflozin-a post-hoc analysis of the UTOPIA study [J].
Katakami, Naoto ;
Mita, Tomoya ;
Sato, Yasunori ;
Watada, Hirotaka ;
Shimomura, Iichiro .
DIABETOLOGY INTERNATIONAL, 2024, 15 (03) :379-388
[49]   Comparison of efficacy and safety of two starting insulin regimens in non-Asian, Asian Indian, and East Asian patients with type 2 diabetes: a post hoc analysis of the PARADIGM study [J].
Ji, Linong ;
Min, Kyung Wan ;
Oliveira, Juliana ;
Lew, Thomas ;
Duan, Ran .
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2016, 9 :243-249
[50]   Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once-weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1-5, 7-10 and SUSTAIN China [J].
Ji, Linong ;
Ahmann, A. J. ;
Ahren, B. ;
Capehorn, M. S. ;
Hu, P. ;
Lingvay, I. ;
Liu, W. ;
Rodbard, H. W. ;
Shen, Z. ;
Sorli, C. .
DIABETES OBESITY & METABOLISM, 2024, 26 (01) :233-241